There are no files associated with this item.
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.citation.startPage | 106754 | - |
dc.citation.title | LEUKEMIA RESEARCH | - |
dc.citation.volume | 112 | - |
dc.contributor.author | Kee, Kyung-Mi | - |
dc.contributor.author | Kim, Soo-Hyun | - |
dc.contributor.author | Yang, Seon-Young | - |
dc.contributor.author | Shin, Jeong-U | - |
dc.contributor.author | Nam, Yoon-Won | - |
dc.contributor.author | Jang, Eun-Jung | - |
dc.contributor.author | Kim, Hongtae | - |
dc.contributor.author | Lee, Semin | - |
dc.contributor.author | Park, Sung Ho | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.date.accessioned | 2023-12-21T14:42:53Z | - |
dc.date.available | 2023-12-21T14:42:53Z | - |
dc.date.created | 2022-01-07 | - |
dc.date.issued | 2022-01 | - |
dc.description.abstract | To compare the clinical significance of 3-month cytogenetic and molecular monitoring, we analyzed 1,410 paired cytogenetic and molecular data from 705 chronic-phase chronic myeloid leukemia patients. Based on early cytogenetic response (ECyR, Ph+≤35 %) and molecular response (EMR, BCR-ABL1IS≤10 %) at 3 months, the patients were divided into four groups (group 1: ECyR + EMR, n = 560; group 2: no ECyR + EMR, n = 27; group 3: ECyR + no EMR, n = 55; group 4: no ECyR + no EMR, n = 63). By 10 years, major molecular response (MMR), deep molecular response (MR4.5), overall survival (OS), and progression-free survival (PFS) rates were significantly high in group 1 (P < 0.001). Comparing groups 2 and 3, the MMR (P = 0.096), MR4.5 (P = 0.945), OS (P = 0.832), and PFS (P = 0.627) rates tended to be higher in group 2, although not significantly. Thus, the cytogenetic assay can not only be useful but its addition may also provide a more precise prediction of MR4.5. | - |
dc.identifier.bibliographicCitation | LEUKEMIA RESEARCH, v.112, pp.106754 | - |
dc.identifier.doi | 10.1016/j.leukres.2021.106754 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.scopusid | 2-s2.0-85121236079 | - |
dc.identifier.uri | https://scholarworks.unist.ac.kr/handle/201301/56564 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0145212621017550?via%3Dihub | - |
dc.identifier.wosid | 000800672300003 | - |
dc.language | 영어 | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia | - |
dc.type | Article | - |
dc.description.isOpenAccess | FALSE | - |
dc.relation.journalWebOfScienceCategory | Oncology;Hematology | - |
dc.relation.journalResearchArea | Oncology;Hematology | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | Early response | - |
dc.subject.keywordAuthor | Cytogenetic response | - |
dc.subject.keywordAuthor | Molecular response | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
dc.subject.keywordPlus | POLYMERASE-CHAIN-REACTION | - |
dc.subject.keywordPlus | BCR-ABL | - |
dc.subject.keywordPlus | TRANSCRIPT LEVELS | - |
dc.subject.keywordPlus | IMATINIB MESYLATE | - |
dc.subject.keywordPlus | PHASE | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordPlus | PREDICTS | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordPlus | CML | - |
dc.subject.keywordPlus | ACHIEVEMENT | - |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Tel : 052-217-1404 / Email : scholarworks@unist.ac.kr
Copyright (c) 2023 by UNIST LIBRARY. All rights reserved.
ScholarWorks@UNIST was established as an OAK Project for the National Library of Korea.